Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.46 |
| ▸ | CTPS1 | P17812 | 11/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 2/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24369696 | 1.00 | SCN9A (0.46) | SCN9ACTPS1HSD11B1PARP1CHRNB2 | |
| SCHEMBL24369439 | 0.78 | CTPS1 (0.41) | CTPS1CHRNB2CHRNA4 | |
| SCHEMBL24369681 | 0.78 | CTPS1 (0.41) | CTPS1CHRNB2CHRNA4 | |
| SCHEMBL24369093 | 0.73 | CHRNB2 (0.38) | CHRNB2CHRNA4 | |
| SCHEMBL25098486 | 0.72 | OPRM1 (0.44) | CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL24369034 | 0.71 | SCN9A (0.50) | SCN9ACTPS1 | |
| SCHEMBL16827647 | 0.71 | SCN9A (0.50) | SCN9ACTPS1 | |
| SCHEMBL29464233 | 0.71 | SCN9A (0.50) | SCN9ACTPS1 | |
| SCHEMBL18802292 | 0.71 | ALDH1A1 (0.55) | SCN9ACTPS1HSD11B1 | |
| SCHEMBL18725653 | 0.71 | SCN9A (0.50) | SCN9ACTPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230077316-A1 | CTPS1 INHIBITORS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2023-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230077316-A1 | CTPS1 INHIBITORS AND USES THEREOF | CTPS1, CTPS2, ECHS1 | SCN9A 4544/4885CTPS1 1/4885HSD11B1 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.